Table 2.

FDA-approved therapies for PsA, RA, and OA

Class	PsA [3, 105, 144]	RA [145, 146]	OA [147–149]
csDMARDs	MTX, leflunomide, sulfasalazine, cyclosporine	MTX, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine
bDMARDs	TNFis: etanercept, infliximab, adalimumab, golimumab, certolizumab pegol IL-17 inhibitors: secukinumab, ixekizumab IL-12/23 inhibitor: ustekinumab IL-23 inhibitor: guselkumab T-cell activation inhibitor: abatacept	TNFis: etanercept, infliximab, adalimumab, golimumab, certolizumab pegol IL-6 receptor antagonists: tocilizumab, sarilumab IL-1 receptor antagonist: anakinra T-cell activation inhibitor: abatacept CD20 inhibitor: rituximab
tsDMARDs	PDE4 inhibitor: apremilast JAK inhibitor: tofacitinib	JAK inhibitors: tofacitinib, baricitinib, upadacitinib
Other	Corticosteroid injections NSAIDs	Corticosteroid injections NSAIDs	Corticosteroid injections NSAIDs Opioids: tramadol Non-pharmacological interventions:   Exercise   Weight management   Strength training   Self-management and education

bDMARD biologic DMARD, csDMARD conventional synthetic DMARD, DMARD disease-modifying antirheumatic drug, IL interleukin, JAK Janus kinase, MTX methotrexate, NSAID nonsteroidal anti-inflammatory drug, OA osteoarthritis, PsA psoriatic arthritis, PDE4 phosphodiesterase 4, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitor, tsDMARD targeted synthetic DMARD